TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT02470169

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Merional
Description: On the 3rd day of menstruation women will have a vaginal ultrasound and will receive daily intramuscular 150 IU of human menopausal gonadotropins (hMG, Merional ®, IBSA, Lugano, Switzerland) starting from the 3nd day of menstruation.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: IUI
Description: Semen will be processed and drawn into a shepherd catheter attached to a 1 mL syringe and injected into the uterus

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: IUI
Description: Semen will be processed and drawn into a shepherd catheter attached to a 1 mL syringe and injected into the uterus

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Choriomon
Description: Administration of 10000 IU of human chorionic gonadotropin (hCG; Choriomon®, IBSA) when at least 2 follicles measuring 18 mm are observed during vaginal ultrasound and is associated with serum E2 of 500-3000 Pg/mL

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: shepherd catheter

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: shepherd catheter

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Ovulation detection
Description: Women will be asked to test their morning urine specimen for luteinizing hormone daily starting 4 days before the expected day of ovulation. This will be done using a qualitative kit

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Ovulation detection
Description: Women will be asked to test their morning urine specimen for luteinizing hormone daily starting 4 days before the expected day of ovulation. This will be done using a qualitative kit
Study: NCT01085513

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: PillCam SB2
Description: The disposable, ingestible PillCam SB 2 Capsule, part no. FGS-0180, is designed to acquire video images during natural propulsion through the small bowel. The capsule transmits acquired images via RF communication channel to the DataRecorder located outside the body.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: PillCam SB2
Description: The disposable, ingestible PillCam SB 2 Capsule, part no. FGS-0180, is designed to acquire video images during natural propulsion through the small bowel. The capsule transmits acquired images via RF communication channel to the DataRecorder located outside the body.
Study: NCT04124952

Intervention type: DEVICE
Intervention: Panoptix
Description: Alcon Acrysof(R) Panoptix(R) intraocular lens (IOL)
Study: NCT03603340

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: ENDS (vaporizer/e-cig) and smoking cessation counseling
Description: Participants in the intervention group will receive an ENDS and nicotine-containing e-liquids, which they will be allowed to use ad libitum. Additionally, they will receive smoking cessation counseling. Participants will be allowed to additionally use nicotine replacement therapy. All participants will be followed over a 24-month period. Smoking cessation counseling will be provided in person at the first clinical visit and then over the phone at the target quit date one week later and again at week 2, 4 and 8 after the target quit date. After 6, 12 and 24 months, participants will be asked to come to a clinical visit.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Smoking cessation counseling
Description: Participants in the control group will receive smoking cessation counseling only. Participants will be allowed to additionally use nicotine replacement therapy. All participants will be followed over a 24-month period. Smoking cessation counseling will be provided in person at the first clinical visit and then over the phone at the target quit date one week later and again at week 2, 4 and 8 after the target quit date. After 6, 12 and 24 months, participants will be asked to come to a clinical visit.
Study: NCT02286336

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: brachial plexus block
Description: brachial plexus block with ropivacaine 40ml

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: brachial plexus block
Description: brachial plexus block with ropivacaine 40ml
Study: NCT02082652

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Etonogestrel
Description: Etonogestrel single-rod subdermal implant (68mg/rod) is placed upon enrollment (day 0) and remains in place until participant requests removal or for the duration of active drug (currently approved for 3 years of use).

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Etonogestrel
Description: Etonogestrel single-rod subdermal implant (68mg/rod) is placed upon enrollment (day 0) and remains in place until participant requests removal or for the duration of active drug (currently approved for 3 years of use).

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Etonogestrel
Description: Etonogestrel single-rod subdermal implant (68mg/rod) is placed upon enrollment (day 0) and remains in place until participant requests removal or for the duration of active drug (currently approved for 3 years of use).
Study: NCT03542305

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lorlatinib
Description: Lorlatinib single oral dose
Study: NCT03727685

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Our Care Wishes
Description: A flyer describing the Our Care Wishes platform will be added to the back pocket of admission packets for patients being admitted via the Silverstein 1 Admission Office and the Emergency Department and for patients being seen in the Pre Admission Testing office. Registration reps in these locations will inform all patients seen that Penn has created a free, online resource called Our Care Wishes to help patients with Advance Care Planning and ask if they would like to be sent a link to Our Care Wishes by email or text. For those patients who respond affirmatively, the rep will then complete the necessary fields to refer on www.ourcarewishes.org/refer.
Study: NCT03542305

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lorlatinib
Description: Lorlatinib single oral dose

Intervention type: DRUG
Group type: OTHER
Intervention: Lorlatinib
Description: Lorlatinib single oral dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lorlatinib
Description: Lorlatinib single oral dose
Study: NCT02741505

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Actigraph
Description: Participants will be asked to wear an actigraph
Study: NCT02565966

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Modified Atkins Diet (MAD)
Description: For those in the MAD intervention group, the dietitian trains the patient and family in the preparation and management of this specialized therapy including sick-day guidelines, meal planning, carbohydrate counting and trouble-shooting. Written and verbal education including, but not limited to: recipes, education materials, sample meal plans and carbohydrate counters are provided to the patient during the initial education session. The caregiver/patient is trained in the outpatient setting and the diet is implemented at home with as much email/phone support from the dietician and ketogenic team as the patient needs to successfully maintain the diet. Medications are all changed over to the lowest carbohydrate forms to eliminate excess carbohydrate intake and all patients are started on vitamin supplements to maintain adequate nutrition.
Study: NCT02195856

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Beetroot juice
Description: 140mL concentrated Beetroot juice or placebo juice

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study: NCT00649857

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cetirizine HCl Tablets 10 mg
Description: 10mg, single dose fed

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Zyrtec® 10 mg
Description: 10mg, single dose fed
Study: NCT02024217

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: S1，oxaliplatin，radiation
Description: Radiation: 180 (cGy) /day, D1-5;S1: 50mg/m2,D1-5;
Study: NCT01793779

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: cold water immersion

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: cold water immersion
Study: NCT04543565

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pradefovir Mesylate;Placebo of Tenofovir disoproxil fumarate tablet
Description: Once daily
Study: NCT01793779

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: beta-hydroxy-beta-methylbutyrate free acid (HMB-FA)

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: beta-hydroxy-beta-methylbutyrate free acid (HMB-FA)

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Placebo
Study: NCT05302115

Intervention type: DEVICE
Intervention: S-ICD
Description: Implantation of an S-ICD
Study: NCT02322372

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Femoral blockade
Description: Spinal anesthesia with heavy bupivacaine combined with femoral blockade with bupivacaine
Study: NCT04543565

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tenofovir disoproxil fumarate tablet;Placebo of Pradefovir Mesylate
Description: Once daily
Study: NCT01108224

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Psychosocial support
Description: Psycho-social group intervention including patient-education for 6 h per week for 2 weeks and group therapy 2½ h for 8 weeks
Study: NCT01702402

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Educational and Behavior Change intervention
Description: Integrate post-partum family planning education and counselling into 2nd Antenatal Home visit by CHW (at approximately 32 weeks of pregnancy) Integrate post-partum family planning education and counselling into post-partum visits by CHWs during first month Continue providing family planning education and counselling to women through CHW home visits after first month.~Promote discussion and acceptance of post-partum family planning methods among key household members.~Facility level Ensure availability of postpartum contraceptive methods such as progestin-only pill.~Ensure availability of post-partum family planning and post-natal services. Community level Increase community awareness of the importance of birth spacing and benefits of LAM Educate influential community members on the importance of birth spacing and benefits of LAM.

Intervention type: OTHER
Group type: OTHER
Intervention: Comparison Group
Description: A comparison area received standard government health services.
Study: NCT00161720

Intervention type: DRUG
Intervention: Protein C Concentrate (Human) Vapor Heated
Description: Protein C Concentrate (Human) Vapor Heated
Study: NCT03769857

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: NEM® + BIOCURC®
Description: Dietary supplement combination for the support of joint health.

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo
Study: NCT02972294

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Iron Isomaltoside 1000
Description: Iron Isomaltoside 1000 will be use. Blinding procedure will be put in place for the administration of the treatment

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Iron Isomaltoside 1000
Description: Iron Isomaltoside 1000 will be use. Blinding procedure will be put in place for the administration of the treatment

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tranexamic Acid
Description: Tranexamic acid will be use.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tranexamic Acid
Description: Tranexamic acid will be use.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebos iron isomaltoside 1000
Description: placebo of Iron Isomaltoside 1000 correspond to a saline solution. Blinding procedure will be put in place for the administration of this treatment

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebos iron isomaltoside 1000
Description: placebo of Iron Isomaltoside 1000 correspond to a saline solution. Blinding procedure will be put in place for the administration of this treatment

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebos tranexamic acid
Description: placebo of tranexamic acid correspond to a saline solution.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebos tranexamic acid
Description: placebo of tranexamic acid correspond to a saline solution.
Study: NCT01011764

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: SKILLS vs ENGAGE
Description: The investigators plan to contrast 2 different models for social skills groups. Each model involves 16 45-minute bi-weekly sessions, twice a week with a small group of children with ASD. Details of the 2 intervention models are described below.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: SKILLS vs ENGAGE
Description: The investigators plan to contrast 2 different models for social skills groups. Each model involves 16 45-minute bi-weekly sessions, twice a week with a small group of children with ASD. Details of the 2 intervention models are described below.
Study: NCT00741910

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Semapimod
Description: semapimod IV 60 mg x 3 days q 6 - 10 weeks
Study: NCT03082768

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: [18F]MNI-968
Description: Healthy volunteers recruited for the study will undergo two \[18F\]MNI-968 injections and PET scans.
Study: NCT01444144

Intervention type: OTHER
Intervention: Fracture union
Description: Retrospective records review post-operatively until fracture resolved.
Study: NCT00671515

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pioglitazone
Description: An open-label 12-week trial of pioglitazone monotherapy. The investigators will titrate pioglitazone to the maximum tolerable dose up to 45mg per day.
Study: NCT03907293

Intervention type: BEHAVIORAL
Intervention: Exercise-based cardiac rehabilitation
Description: Moderate intensity aerobic exercise, lifestyle advice, and psychological support.
Study: NCT02324413

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Clonidine
Description: Comparison between placebo and 2 different concentrations of clonidine

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study: NCT02340936

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LR-ESHAP (lenalidomide 5 mg)
Description: 3 cycles of lenalidomide 5mg, etoposide, methylprednisolone, cisplatin, cytarabine and rituximab every 3 weeks.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LR-ESHAP (lenalidomide 10 mg)
Description: 3 cycles of lenalidomide 10mg, etoposide, methylprednisolone, cisplatin, cytarabine and rituximab every 3 weeks.
Study: NCT03447990

Intervention type: DRUG
Group type: OTHER
Intervention: MYK-491
Description: Single Ascending Dose and Multiple Ascending Dose of MYK-491
Study: NCT03447990

Intervention type: DRUG
Group type: OTHER
Intervention: Placebo
Description: Single Ascending Dose and Multiple Ascending Dose of placebo
Study: NCT03287505

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aripiprazole IM Depot
Description: administration of Aripiprazole IM Depot formulation at doses of 300 and 400mg once in patients with schizophrenia.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aripiprazole IM Depot
Description: administration of Aripiprazole IM Depot formulation at doses of 300 and 400mg once in patients with schizophrenia.
Study: NCT04356274

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Participatory System Dynamics (PSD)
Description: Participatory system dynamics is a facilitated health care quality improvement or evidence-based practice implementation strategy that includes frontline addiction and mental health staff running simulations of clinic improvement strategies to find the best approaches for improving the reach of evidence-based psychotherapy and evidence-based pharmacotherapy.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Audit and Feedback (AF)
Description: Audit and feedback is a health care quality improvement or evidence-based practice implementation strategy that includes frontline addiction and mental health staff reviewing clinical care team data to find the best approaches for improving the reach of evidence-based psychotherapy and evidence-based pharmacotherapy.
Study: NCT02322372

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Intrathecal anesthesia
Description: Spinal anesthesia with heavy bupivacaine
Study: NCT02767999

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fluoxetine
Description: 20 mg of fluoxetine capsule per day from D0 to D90

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: cellulose placebo per day from D0 to D90

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: fMRI
Description: functional resting state MRI

Intervention type: RADIATION
Group type: PLACEBO_COMPARATOR
Intervention: fMRI
Description: functional resting state MRI
Study: NCT00766909

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cyclosporine
Description: For Healthy volunteers (study 1) and Dialysis patients (study 2): Single intravenous infusion of 0.155 mg/kg over a maximum duration of 5 hours.~For Dialysis Patients (study 2): Oral intake of 4 mg/kg 2 times daily for 8-11 days.
Study: NCT04706273

Intervention type: DEVICE
Intervention: GORE® VIABAHN® Endoprosthesis
Description: Participants receiving the GORE® VIABAHN® Endoprosthesis
Study: NCT01279551

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 0.4% nitroglycerin ointment
Description: Local endoanal application 2 times a day

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: lidocaine cloridrato 2.5% ointment
Description: Local endoanal application of lidocaine cloridrato 2.5% ointment 2 times a day
Study: NCT00412022

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: tamoxifen
Description: 20 mg daily for 5 years

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: triptorelin
Description: Premenopausal patients will receive triptorelin 3.75 mg IM at the beginning of therapy and every 4 weeks for 5 years or up to age 55

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: triptorelin
Description: Premenopausal patients will receive triptorelin 3.75 mg IM at the beginning of therapy and every 4 weeks for 5 years or up to age 55

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: triptorelin
Description: Premenopausal patients will receive triptorelin 3.75 mg IM at the beginning of therapy and every 4 weeks for 5 years or up to age 55

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: letrozole
Description: 2.5 mg daily for 5 years

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: letrozole
Description: 2.5 mg daily for 5 years

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: zoledronic acid
Description: 4 mg every 6 months
Study: NCT03996954

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Alivecor recording
Description: Alivecor recording and ECG recording from the same patient in very close temporal proximity
Study: NCT00766909

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: tacrolimus
Description: For Healthy volunteers (study 1) and Dialysis patients (study 2): Single intravenous infusion of 0.0012 mg/kg over a maximum duration of 5 hours.~For Dialysis Patients (study 2): Oral intake of 0.1 mg/kg 2 times daily for 8-11 days.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Capsules and isotonic saline
Description: For Healthy volunteers (study 1) and Dialysis patients (study 2): Single intravenous infusion of 0.06 ml/kg isotonic saline over a maximum duration of 5 hours.~For Dialysis patients (study 2): Placebo capsules 2 times daily for 8-11 days.
Study: NCT03861052

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tirzepatide
Description: Administered SC

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tirzepatide
Description: Administered SC

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tirzepatide
Description: Administered SC

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dulaglutide
Description: Administered SC
Study: NCT04154007

Intervention type: DIAGNOSTIC_TEST
Intervention: kidney function tests - urine output
Description: AKI was classified based on the worst of either creatinine or urine output criterion as follows:~Stage I 1.5-1.9 times baseline OR ≥0.3 mg/dl increase in the serum creatinine, OR urine output \<0.5 ml/kg per hour for 6 to 12 hours.~Stage II 2.0-2.9 times baseline increase in the serum creatinine OR urine output \<0.5 ml/kg per hour for ≥12 hours.~Stage III 3.0 times baseline increase in the serum creatinine OR increase in serum creatinine to ≥4.0 mg OR urine output of \<0.3 ml/kg per hour for ≥24 hours, OR anuria for ≥12 hours OR the initiation of renal replacement therapy.
Study: NCT04181099

Intervention type: OTHER
Group type: OTHER
Intervention: Implant neck surface
Description: The biofilm formation is tested on discs manufactured of zirconia with different surfaces in vivo using orthodontic devices that the participants carry over 24h
Study: NCT01487837

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Human fibrinogen concentrate
Description: Administration of human fibrinogen concentrate (30 mg / kg bw) over 15 min Repetition if hourly intraoperative ROTEM measurements revealed hypofibrinogenemia according to treatment group definition

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Human fibrinogen concentrate
Description: Administration of human fibrinogen concentrate (30 mg / kg bw) over 15 min Repetition if hourly intraoperative ROTEM measurements revealed hypofibrinogenemia according to treatment group definition
Study: NCT02340936

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LR-ESHAP (lenalidomide 15 mg)
Description: 3 cycles of lenalidomide 15mg, etoposide, methylprednisolone, cisplatin, cytarabine and rituximab every 3 weeks.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LR-ESHAP (lenalidomide 20 mg)
Description: 3 cycles of lenalidomide 20mg, etoposide, methylprednisolone, cisplatin, cytarabine and rituximab every 3 weeks.
Study: NCT01713907

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Ulthera® Treatment
Description: Focused ultrasound energy delivered below the surface of the skin.
Study: NCT03802201

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PTG-300
Description: Subcutaneous (SC)
Study: NCT02336191

Intervention type: PROCEDURE
Intervention: living donor liver transplantation
Description: living donor liver transplantation
Study: NCT02331173

Intervention type: DRUG
Intervention: Dorzolamide 2% TID or brinzolamide 1% TID
Description: Dosing of all medications will be based upon standard of care. Standard dosing for the treatment of pediatric and adult patients with XLRS is as follows:~* Topical dorzolamide 2% three times per day~* Topical brinzolamide 1% three times per day